Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02772276 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
A Phase 2 study, sponsored by MediBeacon.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT02772276 is a Phase 2 study that has completed, run by MediBeacon. The registered enrollment target is 234 participants.
The verdict
NCT02772276, a Phase 2 study, has completed, sponsored by MediBeacon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
This study was a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use of the non-invasive optical renal function monitor (ORFM) device in normal and compromised renal function participants with different skin color types.
Interventions
- DRUG Iohexol
- DRUG MB-102-- single dose of 4 µmol/kg
- DRUG MB-102-- single dose of 130 mg
- DRUG MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
- DRUG MB-102-- two doses of 130 mg 24 hours apart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2021-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02772276
The ClinicalTrials.gov registry entry for NCT02772276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediBeacon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Iohexol is the first listed.
NCT02772276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02772276 about?
NCT02772276 is a clinical study titled "Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types". This study was a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use of the non-invasive optical renal function monitor (ORFM) device in normal and compromised renal function participants with different skin color types.
What is the current status of trial NCT02772276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2016-05-11. Estimated completion is 2021-08-04.
What interventions are being tested in trial NCT02772276?
The interventions under investigation include: Iohexol (DRUG), MB-102-- single dose of 4 µmol/kg (DRUG), MB-102-- single dose of 130 mg (DRUG), MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart (DRUG), MB-102-- two doses of 130 mg 24 hours apart (DRUG).
Who is sponsoring clinical trial NCT02772276?
This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.